Introduction
Estrogen plays an important role not only in cell growth, differentiation, and apoptosis in various normal organs but also in benign and malignant tumors as well [1, 2] . Most estrogen has been believed to be synthesized depending on the expression of aromatase in the ovary and placenta in premenopausal women. However, the secretion of biologically active estrogen in situ through the conversion of circulating precursor androgens has been demonstrated to play important roles not only in normal extraovarian tissues [3] [4] [5] but also in estrogendependent carcinomas, including breast and ovarian cancers [6, 7] .
Until the discovery of estrogen receptors (ERs) in human gastric cancer tissues, by Tokunaga et al. [8] in 1986, the stomach was not believed to be a direct target organ for estrogen. Since then, a number of investigators have demonstrated the expression of ERα and β mRNAs in both tumoral and nontumoral tissues from gastric cancer patients [9] [10] [11] . Of note, a pioneering study by Saitoh et al. [12] suggested the mechanism of estrogen production by aromatase in gastric carcinoma. Ueyama et al. [13] recently demonstrated aromatase expression and estrogen secretion in rat parietal cells of the gastric mucosa. Against the background of these observations, in the present study we further evaluated the ability of gastric carcinoma to secrete estrogen depending on the expression of aromatase.
Using a quantitative real-time polymerase chain reaction (PCR) and exon I-specifi c reverse transcription (RT)-PCR, we demonstrated the molecular basis of aromatase mRNA expression in gastric carcinoma for the fi rst time. To support this observation, we submitted gastric tissue sections to immunohistochemical analysis, using an anti-aromatase monoclonal antibody.
Patients, materials, and methods

Patients and tissue preparation
Nineteen specimens of gastric carcinoma were obtained from Japanese patients at the Department of Surgery, Tottori University Hospital, Yonago, Japan. Nontumoral tissues adjacent to the carcinoma were also available for analysis. The histological features of the gastric carcinomas were as follows: 8 intestinal-type and 11 diffuse-type adenocarcinomas. Tissue specimens removed at surgery were immediately either stored in RNAlater (Ambion, Tokyo, Japan) for the preparation of RNA (5 specimens) or submitted to formalin-fi xation and paraffi n-embedding for immunohistochemical analysis (14 specimens). Informed consent was obtained from all patients before surgery. Approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Tottori University (approval number, 283).
Cell culture
Six cell lines derived from human gastric cancers were used throughout the experiments. MKN-1 was established from an adenosquamous carcinoma [14] . MKN-28 was established from a well-differentiated adenocarcinoma [14] . MKN-45 [14] and MKN-74 [15] were established from a poorly differentiated and a well-differentiated adenocarcinoma, respectively. KATO-III [15, 16] and HSC-39 [17] were established from a signet-ring cell carcinoma. COS-1 monkey kidney tumor cell was used in the analysis of exogenous aromatase. Cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) at 37℃ under 5% CO 2 .
17b-Estradiol (E 2 ) secretion assay
The ability of gastric cancer cells to secrete E 2 was evaluated by quantifying the E 2 level in the culture medium. In brief, cells were plated at a density of 1 × 10 5 cells per well in a 12-well plate, and cultured in RPMI 1640 supplemented with 10% FCS for 24 h. Then the culture media were changed to FCS-free RPMI 1640 supplemented with or without 10 −5 M testosterone. Eight hours after the media change, the E 2 concentration was assayed, using an enzyme immunoassay (EIA) kit (Amerlite P; Amersham Pharmacia, Tokyo, Japan).
Aromatase assay
Aromatase activity in vitro was determined by measuring the amount of tritiated water released upon the conversion of [1β- 3 H] androstenedione to estrone, according to the method of Ackerman et al. [4] , with minor modifi cation. In brief, cells were scraped off the culture dishes or recovered by brief centrifugation with 0.1 M phosphate buffer (pH 7.6), and then subjected to sonication for 5 min at 4 ˚C, using a Bioruptor (Cosmo Bio, Tokyo, Japan). The resultant cell lysates were then subjected to centrifugation at 1000 rpm for 3 min at 4 ˚C, and the supernatant was used for the aromatase assay. Following the addition of [1β-
3 H] androstenedione (5 nM, 936 GBq/mmol; NEN Life Science Products, Boston, MA, USA) and nicotinamide adenine dinucleotide phosphate, reduced (NADPH) buffer, the supernatant was incubated for 60 min at 37 ˚C. At the end of the incubation, the reaction mixture was extracted with chloroform and then treated with dextran-coated charcoal to remove the remaining [1β-3 H] androstenedione. After brief centrifugation, [ 3 H]-H 2 O included in the supernatant was assayed in a liquid scintillation counter (LSC-6100; ALOKA, Tokyo, Japan). The protein concentration was determined by the method of Bradford [18] .
Analysis of aromatase mRNA expression and alternative promoter usage
Total cellular RNA was prepared using the RNeasy kit (QIAGEN, Tokyo, Japan) according to the manufacturer's protocol. Using 2 μg of total RNA as template, single-stranded cDNA was prepared in 20 μl of reaction mixture, containing 1 mM each of dNTP, 50 units of murine leukemia reverse transcriptase (Applied Biosystems, Branchburg, NJ, USA), 20 units of RNase inhibitor (RNasin; Promega, Madison, WI, USA) and oligo-dT 16 primer at 37 ˚C for 90 min. Then, 1 μl of the cDNA reaction mixture was subjected to PCR amplification in 50 μl of PCR mixture containing 0.25 units of ExTaq polymerase (Takara, Kyoto, Japan) and 50 pmol each of forward (AromF, 5′-GACTCTAAATTGC CCCCTCTGA-3′ in Exon II) and reverse (AromR, 5′-CATGCTGGAAATGATCTTTACCC-3′ in Exon X) primers, which were designed from the human placenta aromatase cDNA sequence (GenBank accession number, M22246) to amplify the sequence corresponding to the total open reading frame (ORF; 1517 bp). The conditions for PCR were 1 min at 94 ˚C, 1 min at 62 ˚C, and 1 min at 72 ˚C, for 38 cycles. At the end of the PCR cycles, 18 μl of the reaction mixture was removed and electrophoresed on a 1.5% agarose gel in Tris-borateethylenediaminetetraaceticacid (EDTA) buffer at a constant voltage of 100 V. At the end of the electrophoresis, the gel was removed and visualized by staining with ethidium bromide. As an internal control, β-tubulin mRNA expression was monitored. The primer sets to amplify a 577-bp sequence were: 5′-TGGATCT AGAACCTGGGACC-AT-3 (sense) and 5′-ACCATG TTGACTGCCAACTTGC-3′ (anti-sense). In the promoter assay, unique exon I primers (PII, I.1, I.3, I.4, I.5, and I.6) and exon II primers were used, as described previously [19] . GenBank locations and accession numbers for the specifi c primers are: I.1, 708-727, M32245; I.3, 867-887,S85356; I.4, 512-531, D21240; I.5, 619-642, S71536; I.6, 161-181, S85356; PII, 965-984, S85356; exon II-f, 1030-1050, S85356; exon II-r, 1198-1179, S85356. The PCR condition was 1 min at 94 ˚C, 1 min at 54 ˚C, and 1 min at 72 ˚C, for 35 cycles. At the end of the PCR cycles, 10 μl of the reaction mixture was removed and electrophoresed as described above. Separated DNA fragments were then transferred to a nylon membrane (Hybond N+; GE Healthcare, Buckinghamshire, UK), and hybridized to 32 P-labeled aromatase exon II cDNA at 42 ˚C for 18 h in a solution containing 50% formamide, 5 × standard saline citrate (SSC), 10 × Denhardt's solution 50 mM sodium phosphate buffer (pH 6.5), salmon testis DNA (100 μg/ml), and 1% sodium dodecyl sulfate (SDS). At the end of the hybridization period, the nylon membrane was removed, washed according to the manufacturer's protocol, and exposed to BioMax fi lm (Eastman Kodak, Rochester, NY, USA).
Quantitative real-time PCR
Total cellular RNAs and single-stranded cDNAs were prepared, as described above, from the tissue specimens and cell lines, and aromatase mRNA expression was assessed using real-time PCR. As an internal control, β-tubulin mRNA expression was assessed in parallel. In brief, 1 μl each of the cDNA samples (∼50 ng) as indicated above was subjected to TaqMan real-time PCR in triplicate. The real-time PCR was performed using the Universal Probe Library system (Roche Diagnostics, Tokyo, Japan). The specifi c probes (aromatase #55 and β-tubulin #43) were selected on the Web site of the Universal Probe Library Assay Design Center (https://www. roche-applied science.com/sis/rtpcr/upl/adc.jsp). FastStart TaqMan Probe Master (Roche Diagnostics) was used for the reaction solution. Finally, the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Tokyo, Japan) was used for the real-time PCR.
Aromatase expression vector and the transient expression
Single-stranded cDNA was prepared from the total cellular RNA of MKN-74 cells. Using the cDNA as a template, a 1559-bp sequence encoding the total ORF of aromatase was amplifi ed by PCR, as described above. The primer set used was AromF (in exon ll) and 5′-CCAGCCTTCTCTAGTGTTCCAG-3′ (in exon X). The amplifi ed cDNA sequence was cloned into the HindIII/EcoRV sites of pcDNA3 (Invitrogen, Tokyo, Japan). COS-1 cells were transfected with either pcDNA3 or pcDNA3/aromatase, using FuGENE6 reagent (Roche Diagnostics). The transfection effi ciency was more than 80%. Twenty four hours after the transfection, the cells were used for Western blot analysis.
Western blot analysis
Cells were scraped off the dishes and suspended in icecold 10% trichloroacetic acid for 10 min. Following centrifugation at 15 000 g for 10 min at 4 ˚C, the resultant precipitates were solubilized into sample buffer (125 mM Tris-HCl [pH 6.8], 2.3% SDS, 10% glycerol, 20 μg/ml bromophenol blue, and 5% 2-mercaptoethanol), and then incubated in boiling water for 5 min. The protein sample (10 μg) was electrophoresed on a 10% SDS-polyacrylamide gel (150 V, for 80 min) and electrophoretically transferred to a polyvinylidene difl uoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membrane was pre-incubated with phosphate-buffered saline (PBS) containing 5% skim milk and 0.1% Tween 20, and then incubated with antiaromatase mouse monoclonal antibody (H4,1: 250; Serotec, Oxford, UK) at 4 ˚C for 15 h. Then the membrane was incubated with anti-mouse IgG conjugated with horseradish peroxidase (1: 2000; MBL, Osaka, Japan) at room temperature for 1 h and subjected to a chemiluminescence assay (ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA). Finally, the membrane was exposed to BioMax fi lm (Eastman Kodak) at room temperature for appropriate time intervals.
Immunohistochemistry
Formalin-fi xed and paraffi n-embedded tissues were cut into serial tissue sections at a thickness of 4 μm. Following deparaffi nization, the sections were immunostained using the streptavidin-biotin alkaline phosphatase complex method, according to the manufacturer's protocol (HISTOFINE SAB-AP (M) Immunohistochemical Staining Kit; Nichirei, Tokyo, Japan). In brief, the tissue section slides were incubated at room temperature for 20 min in blocking serum to eliminate nonspecifi c binding of the primary antibody. The slides were then serially incubated with an anti-cytochrome P450 aromatase monoclonal antibody (H4, 1: 50; Serotec) [20] overnight at 4 ˚C, followed by incubation with the secondary antibody. As a negative control, the sections were incubated in parallel without the primary antibody. At the end of the incubation with the secondary antibody, the sections were washed and then incubated with streptavidin-alkaline phosphatase reagent. The sections were fi nally visualized with new fuchsin and counterstained with hematoxylin.
Results
Aromatase expression in gastric cancer cell lines
As an initial step to verify aromatase expression in gastric cancer, we examined its expression in gastric cancer cell lines. Using RT-PCR, we demonstrated aromatase mRNA expression in all gastric cancer cell lines examined (Fig. 1A) . The level of aromatase expression depends on the cell type, and here it was similar to or less than that in skin fi broblastic cells, which are known B A C D Fig. 1 . A Aromatase mRNA expression in gastric cancer cell lines. Total cellular RNA and single-stranded cDNA were prepared from gastric cancer cells, and subjected to polymerase chain reaction (PCR). A sequence corresponding to the total open reading frame from exon II to exon X (1518 bp) was amplifi ed and electrophoresed on a 1.5% agarose gel. As an internal control, β-tubulin mRNA was assayed in parallel. The amplifi ed sequence was visualized using ethidium bromide staining under UV light. B Promoter involvement in aromatase mRNA transcription. Using the procedure described by Okubo et al. [19] , unique exon I (PII, I.1, I.3, I.4, I.5, and I.6) and exon II primers were used for exon I-specifi c reverse tran- to express abundant aromatase. Among six promoters examined (Fig. 1B) , PII, I.3, and I.6 were used in MKN-1, MKN-28, MKN-45 and KATO-III cells, while PII, I.4, l.5, and I.6 promoters were used in HSC-39 cells. In MKN-74 cells, two active promoters, PII and I.3, were recognized. None of these cells seemed to secrete E 2 in the culture media during an incubation period of up to 15 h (data not shown). However, in the presence of 5 μM testosterone in the culture, these cells produced E 2 even in a short incubation period of 8 h (Fig. 1C) . Aromatase activity in vitro was demonstrated in all cell lines examined (Fig. 1D) .
Aromatase expression in gastric cancer tissues
To demonstrate aromatase mRNA expression in gastric cancer tissue, tumoral tissues were randomly removed from fi ve patients (three with intestinal-type and two with diffuse-type carcinoma) and subjected to RT-PCR analysis. Representative results from two patients are shown in Fig. 2A . A 1.5-kb sequence corresponding to the expected ORF of aromatase mRNA was amplifi ed. Using quantitative real-time PCR analyses, aromatase mRNA expression was demonstrated in the fi ve gastric cancer tissues examined (Fig. 2B) . The expression level varied depending on the specimens, with an approximately tenfold difference. In these tumoral tissues, PII, I.3, and I.6 promoters were used (Fig. 2C) . At the same time, nontumoral mucosa removed from the same patients was submitted to aromatase mRNA expression analysis in parallel. These tissues were shown to express aromatase mRNA, and the expression levels were similar to the levels in tumoral tissues (Fig. 2B) . The predominant promoters A B C Fig. 2A-C . Aromatase mRNA expression in gastric cancer tissues. Gastric cancer tissues from fi ve patients (three with intestinal-type and two with diffuse-type carcinoma) were removed for the preparation of total cellular RNA. Tumoral tissues (t1, t2, t3, t4, and t5) and nontumoral mucosa (n1, n2, n3, n4, and n5) are indicated, with the numbers shown corresponding to the patient number. A Aromatase mRNA expression. Representative results from two patients, patients 2 and 4. As described in the legend to Fig. 1 , total cellular RNA and single-stranded cDNA were prepared from gastric cancer tissues (t2 and t4) and nontumoral mucosa (n2 and n4), and subjected to PCR. A 1518-bp sequence, corresponding to the total open reading frame, was amplifi ed and separated on 1.5% agarose gel electrophoresis. As an internal control, β-tubulin mRNA (577 bp) was assayed in parallel. The amplifi ed sequence was visualized using ethidium bromide staining under UV light. M, Molecular size marker. B Quantitative analysis of aromatase mRNA expression by real-time PCR. The single-stranded cDNAs used in the experiment whose results are shown in A were subjected to TaqMan real-time PCR in triplicate. Specifi c probes for aromatase (#55) and β-tubulin (#43) mRNAs were selected using the Universal ProbeLibrary System. The ABI PRISM 7900HT Sequence Detection System was used for the PCR. Relative aromatase mRNA expression was estimated using β-tubulin mRNA expression as an internal control. Using the lowest value in nontumoral mucosa (n1) as a unit, values are expressed as arbitrary units. C Promoter usage in aromatase mRNA transcription. Unique exon I (PII, 1.1, 1.3, 1.4, 1.5 , and 1.6) and exon II primers were used for the exon I-specifi c RT-PCR [19] used were identical to those used in the tumoral tissues (Fig. 2C) .
Immunohistochemistry
Immunoreactivity for aromatase was examined in 14 gastric carcinoma specimens. Positive staining was observed in 4 of the 5 intestinal-type sections, and in 4 of the 9 diffuse-type sections. Representative staining for intestinal-type and diffuse-type carcinoma is shown in Fig. 3A and Fig. 3B , respectively. In the nontumoral mucosa, positive staining was observed predominantly in the parietal cells (Fig. 3C) . The monoclonal antibody used above specifi cally recognized a single protein band of aromatase, which had been expressed in COS-1 cells (Fig. 3D) .
Discussion
In the present study, we have demonstrated, for the fi rst time, aromatase mRNA expression, which depended on three proximal promoters, in gastric carcinoma specimens (obtained from 5 patients; Fig. 2 ). Immunohistochemical analysis of gastric carcinoma specimens from 14 patients showed positive staining for aromatase (Fig.  3 ) in 8 specimens. It is important to note that the observation of positive staining for aromatase does not always indicate the exact evaluation of aromatase expression in tissue specimens. Gastric tissues expressing lower levels of aromatase mRNA sometimes exhibit less reactivity to the anti-aromatase monoclonal antibody used in the present study than gastric tissues expressing high levels of aromatase mRNA (data not shown). Interestingly, aromatase mRNA expression was also demonstrated in nontumoral mucosa from the same patients (Fig. 2) . Immunoreactive staining for aromatase in nontumoral mucosa was restricted predominantly to within the parietal cells (Fig. 3C ). This fi nding is consistent with a previous observation in rat gastric mucosa [13] . The observation suggests that the stomach is an endocrine organ that secretes biologically active estrogen. Estrogen secreted in the stomach seems to be trapped in the portal vein and mostly metabolized in the liver [13] . At the same time, estrogen secreted in the stomach may infl uence hepatic function including the estrogen-dependent expression of ERα [13] . If the metabolic activity of liver is lost because of hepatic dysfunction, the estrogen may fl ow out. It is well recognized that gynecomastia occurs against a background of a relative increase in estrogenic activity caused through hepatic fi brosis and cirrhosis [21] [22] [23] .
In our pilot experiments using gastric cancer cell lines (Fig. 1A) , we found a mode of aromatase mRNA expression similar to that seen in gastric carcinoma. Although the expression levels in these cells seemed much lower than the levels in gastric tissues (data not shown), these cells produced a signifi cant level of E 2 in culture media only in the presence of exogenous testosterone (Fig. 1C) . Aromatase activity in vitro was also demonstrated (Fig. 1D) . The lower aromatase mRNA expression in these cell lines may have been caused by an epigenetic disorder of the aromatase gene, as has been suggested to occur in endometriosis [24] . Likewise, epigenetic modifi cation of aromatase gene expression may also occur in gastric carcinoma.
Promoters are well known to be involved in the molecular basis of the differential regulation of aromatase gene expression, in a tissue-specifi c manner. In normal breast adipose tissues, a marginal level of aromatase expression depends on the promoters l.3, l.4, and Pll, while in breast cancer, l.3 and Pll activities were markedly increased along with the upregulation of promoter l.7. The sum of promoter activities (Pll, l.3, l.4, and l.7) markedly upregulated aromatase expression in breast cancer [7] . In gastric cancer, as well as in normal gastric mucosa, we found that the promoters, Pll, l.3, and l.6 were involved in fi ve patients with gastric cancer (Fig. 2C ). At present, it is too early to conclude whether additional promoters are involved in gastric cancer. The question of most interest is whether or not aromatase mRNA expression is higher in tumoral tissues than in normal mucosa. Further study focusing on these issues may help to clarify the pathophysiological role of aromatase expression in gastric cancer.
Recently, a nongenomic action of ERs, without transcriptional effect, which mediates the anti-apoptotic effect of estrogens, has been suggested [25] . Interestingly, ER α and β forms have been demonstrated in gastric carcinoma [8] [9] [10] [11] , and gastric cancer cells exhibited an apoptosis-resistance phenotype [26, 27] , suggesting the pathophysiological behavior of estrogen in gastric carcinoma.
In conclusion, our results provide evidence suggesting a mechanism for secreting biologically active estrogen in gastric carcinoma in vivo, through the conversion of circulating precursor androgens. Further understanding of the molecular basis and the role of estrogen secretion may provide insights into the diagnosis and treatment of gastric cancer.
